In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Rita E. Chen,Emma S. Winkler,James Brett Case,Ishmael D. Aziati,Traci L. Bricker,Astha Joshi,Tamarand L. Darling,Baoling Ying,John M. Errico,Swathi Shrihari,Laura A. VanBlargan,Xuping Xie,Pavlo Gilchuk,Seth J. Zost,Lindsay Droit,Zhuoming Liu,Spencer Stumpf,David Wang,Scott A. Handley,W. Blaine Stine,Pei Yong Shi,Meredith E. Davis-Gardner,Mehul S. Suthar,Miguel Garcia Knight,Raul Andino,Charles Y. Chiu,Ali H. Ellebedy,Daved H. Fremont,Sean P. J. Whelan,James E. Crowe,Lisa A. Purcell,Davide Corti,Adrianus C. M. Boon,Michael S. Diamond +33 more
Reads0
Chats0
TLDR
In this paper, the authors report the in vitro and in vivo activity of a panel of monoclonal antibodies (mAbs) against SARS-CoV-2 variant viruses, which correspond to many mAb combinations in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron and Lilly.Abstract:
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-21-3, the in vivo importance of these results remains uncertain. Here we report the in vitro and in vivo activity of a panel of monoclonal antibodies (mAbs), which correspond to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron and Lilly, against SARS-CoV-2 variant viruses. Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1 and B.1.526 viruses with mutations at residue E484 of the spike protein, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice and hamsters, without the emergence of resistance. Exceptions were LY-CoV555 monotherapy and LY-CoV555 and LY-CoV016 combination therapy, both of which lost all protective activity, and the combination of AbbVie 2B04 and 47D11, which showed a partial loss of activity. When administered after infection, higher doses of several mAb cocktails protected in vivo against viruses with a B.1.351 spike gene. Therefore, many-but not all-of the antibody products with Emergency Use Authorization should retain substantial efficacy against the prevailing variant strains of SARS-CoV-2.read more
Citations
More filters
Journal ArticleDOI
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
TL;DR: In this paper , a randomized, double-blind, placebo-controlled trial involving non-hospitalized patients with Covid-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age ≥ 60 years, obesity, or certain coexisting medical conditions).
Journal ArticleDOI
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan,John M. Errico,Peter Halfmann,Seth J. Zost,James E. Crowe,Lisa A. Purcell,Yoshihiro Kawaoka,Davide Corti,Daved H. Fremont,Michael S. Diamond +9 more
TL;DR: In this paper , the authors tested a panel of anti-receptor-binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309), the parent mAb of VIR-7831 (sotrovimab)), AstraZeneca (COV2-2196 and COV22130, the parentmAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Eli Lilly (LY-CoV555 and LY-Cov016) and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1-Omicron isolate.
Journal ArticleDOI
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Peter Halfmann,Shun Iida,Kiyoko Iwatsuki-Horimoto,Tadashi Maemura,Maki Kiso,Suzanne M. Scheaffer,Tamarand L. Darling,Astha Joshi,Samantha Loeber,Gagandeep Singh,Stephanie L. Foster,Baoling Ying,James Brett Case,Zhenlu Chong,Bradley M. Whitener,Juan I. Moliva,Katharine Floyd,Michiko Ujie,Noriko Nakajima,Mutsumi Ito,R. Wright,Ryuta Uraki,Prajakta Warang,Matthew Gagne,Rongxiu Li,Yuko Sakai-Tagawa,Yanan Liu,Deanna Larson,Jorge E. Osorio,Juan P. Hernández-Ortiz,Amy R. Henry,Karl A Ciuoderis,Kelsey Florek,Mit Patel,Abby E. Odle,Lok-Yin Roy Wong,Allen C. Bateman,Zhongde Wang,Venkata Viswanadh Edara,John Franks,Trushar Jeevan,Thomas P. Fabrizio,Jennifer DeBeauchamp,Lisa Kercher,Patrick Seiler,Ana S. Gonzalez-Reiche,Emilia Mia Sordillo,Lauren A. Chang,Harm van Bakel,Viviana Simon,Bremy Alburquerque,Hala Alshammary,Angela Amoako,Shiraz Aslam,Radhika N. Banu,Cecilia Cognigni,Marlene Espinoza-Moraga,K. Farrugia,Adriana van de Guchte,Z. Khalil,Manon Laporte,Ignacio Mena,Alberto Paniz-Mondolfi,Jose Polanco,A.A. “Sonny” Rooker,L. Sominsky,Daniel C. Douek,Nancy J. Sullivan,Larissa B. Thackray,Hiroshi Ueki,Seiya Yamayoshi,Masaki Imai,Stanley Perlman,Richard J. Webby,Robert A. Seder,Mehul S. Suthar,Adolfo García-Sastre,Michael Schotsaert,Tadaki Suzuki,Adrianus C. M. Boon,Michael S. Diamond,Yoshihiro Kawaoka +81 more
TL;DR: In this paper , the authors evaluated the ability of several B.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters.
Journal ArticleDOI
Tackling COVID-19 with neutralizing monoclonal antibodies
TL;DR: An overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics can be found in this paper.
Journal ArticleDOI
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
AMNH Mammalogy,Michal L. Schwartzman,Juan Hao,Samille Kricia Bezerra de Lima,V. A. Ryzhov,AMNH Mammalogy,Irina Parina +6 more
TL;DR: The RECOVERY trial as mentioned in this paper evaluated the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.
References
More filters
Journal ArticleDOI
UCSF ChimeraX: Meeting modern challenges in visualization and analysis.
Thomas D. Goddard,Conrad C. Huang,Elaine C. Meng,Eric F. Pettersen,Gregory S. Couch,John H. Morris,Thomas E. Ferrin +6 more
TL;DR: This article highlights some specific advances in the areas of visualization and usability, performance, and extensibility in ChimeraX.
Journal ArticleDOI
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
TL;DR: In this paper, the authors show that B.1.7 is refractory to neutralization by most monoclonal antibodies against the N-terminal domain of the spike protein and is relatively resistant to a few monoclanal antibody against the receptor-binding domain.
Journal ArticleDOI
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Journal ArticleDOI
Spike mutation D614G alters SARS-CoV-2 fitness.
Jessica A. Plante,Yang Liu,Jianying Liu,Hongjie Xia,Bryan A. Johnson,Kumari G. Lokugamage,Xianwen Zhang,Antonio E. Muruato,Jing Zou,Camila R. Fontes-Garfias,Divya Mirchandani,Dionna Scharton,John P. Bilello,Zhiqiang Ku,Zhiqiang An,Birte Kalveram,Alexander N. Freiberg,Vineet D. Menachery,Xuping Xie,Kenneth S. Plante,Scott C. Weaver,Pei Yong Shi +21 more
TL;DR: Hamsters infected with SARS-CoV-2 expressing spike D614G (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.
Journal ArticleDOI
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Rui Shi,Chao Shan,Xiaomin Duan,Zhihai Chen,Peipei Liu,Jin-Wen Song,Tao Song,Tao Song,Xiaoshan Bi,Xiaoshan Bi,Chao Han,Lianao Wu,Lianao Wu,Ge Gao,Xue Hu,Ya-Nan Zhang,Zhou Tong,Weijin Huang,William J. Liu,Guizhen Wu,Bo Zhang,Lan Wang,Jianxun Qi,Hui Feng,Fu-Sheng Wang,Qihui Wang,George F. Gao,Zhiming Yuan,Jinghua Yan +28 more
TL;DR: Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.
Related Papers (5)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Christopher O. Barnes,Claudia A. Jette,Morgan E. Abernathy,Kim Marie A. Dam,Shannon R. Esswein,Harry B. Gristick,Andrey G. Malyutin,Naima G. Sharaf,Kathryn E. Huey-Tubman,Yu E. Lee,Davide F. Robbiani,Davide F. Robbiani,Michel C. Nussenzweig,Michel C. Nussenzweig,Anthony P. West,Pamela J. Bjorkman +15 more
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M. Weinreich,Sumathi Sivapalasingam,Thomas Norton,Shazia Ali,Haitao Gao,Rafia Bhore,Bret J Musser,Yuhwen Soo,Diana Rofail,Joseph Im,Christina Perry,Cynthia Pan,Romana Hosain,Adnan Mahmood,John D. Davis,Kenneth C. Turner,Andrea T. Hooper,Jennifer D. Hamilton,Alina Baum,Christos A. Kyratsous,Yunji Kim,Amanda Cook,Wendy Kampman,Anita Kohli,Yessica Sachdeva,Ximena Graber,Bari Kowal,Thomas DiCioccio,Neil Stahl,Leah Lipsich,Ned Braunstein,Gary Herman,George D. Yancopoulos +32 more